Vitreomacular traction (VMT) syndrome is a potentially visually significant disorder of the vitreoretinal interface characterized by an incomplete posterior vitreous detachment with the persistently adherent vitreous exerting tractional pull on the macula and resulting in morphologic alterations and consequent decline of visual function.

2014年7月4日 · Fifty-three eyes with VMT syndrome were categorized into two classifications based on optical coherence tomography images: the VMT morphology (V- or J-shaped) and the diameter of adhesion...

This Clinical Management Guideline outlines the aetiology, signs and symptoms and evidence-based management options for diagnosing PVD, VMA, VMT and macular hole. It provides recommendations for monitoring, referral and summary of possible surgical management.

The paper presents a review of the sequence of events of posterior vitreous detachment (PVD), vitreomacular adhesion (VMA), vitreomacular traction (VMT), and macular hole (MH) from their pathophysiological aspects, clinical features, diagnostic ...

2024年8月27日 · Vitreomacular traction (VMT) occurs when vitreous in the aging eye doesn’t detach completely from the macula. VMT can cause vision loss if left untreated.

2013年10月10日 · Pars plana vitrectomy remains the primary treatment option for many patients with VMT or IMH; for the latter, peeling of the inner limiting membrane (ILM) of the retina has shown...

2013年4月26日 · Optical coherence tomography-based anatomic definitions and classification of vitreomacular adhesion, vitreomacular traction (VMT), and macular hole. Vitreomacular adhesion is defined as perifoveal vitreous separation with remaining vitreomacular attachment and unperturbed foveal morphologic features.

2022年1月1日 · Vitreomacular traction (VMT) refers to an incomplete vitreoretinal separation resulting in retinal structural changes without a full-thickness macular hole. With the advent of more sensitive imaging modalities such as optical coherence tomography, the pathophysiology...

Treatment of VMT and Holes Jetrea (Ocriplasmin) • Alpha-2 antiplasmin reducer • Produces proteolytic activity against protein components within the vitreous body and vitreoretinal interface (laminin, fibronectin, collagen) • FDA approved in 2012 as treatment for VMT • Dosage 0.125 mg

6 天之前 · VMT can be classified in a similar way as in VMA but VMT is usually symptomatic and needs treatment. 24.1.1.2.1 Treatment Options. 1. Observation. This is the main line of treatment for cases with no to mild symptoms. Spontaneous separation may also occur in approximately 30% especially focal and mild VMT. ... Secondary to chronic CMO ...